Klin Onkol 2001; 14(2): 46-50.
Summary: Myeloma cells display considerable phenotypic heterogeneity. All plasma cells express high density CD38 (CD38++). Syndecan-1(CD138 antigen, B-B4) was detected in monoclonal populations CD38+CD45and CD38+CD45dim+ and heterogeneity of its expression was proven. The work presented aimed at preparation of ahigh-purity vital cell suspension of myeloma cells by immunomagnetic separation. There is no significant vitality change, which may be of advantage for experiments in which cultivation of the cells is necessary. Eight samples of aspiration biopsy from patients with multiple myeloma were used. Two methods of separation were evaluated: either positive selection of CD138+ cells or the same method on the fraction which has been depleted of its CD45+ cells. Vitality of the separated cells (median, range) was 98% (97%-99%), purity, as detected flowcytometrically by CD138, was 78.9% (74.9%-87.4%) in one-step and 84.3% (74.8%-94.5%) in twosteps procedures. The purity was further assessed morphologically in one one-step procedure (99.6% of plasma cells) and in one two-steps procedure (100.0% of plasma cells). It displays apreferential contamination with plasma cells without CD138 marker. High purity vital myeloma cells suspension was prepared from bone marrow tissue samples of multiple myeloma patients. Ample application range in the experimental field is suggested.
